Citigroup Inc Celcuity Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Celcuity Inc. stock. As of the latest transaction made, Citigroup Inc holds 19,435 shares of CELC stock, worth $257,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,435

Previous 5,092 281.68%

Holding current value

$257,708

Previous $83,000 248.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$13.98 - $19.15 $200,515 - $274,668	14,343 Added 281.68%	19,435 $289,000
Q2 2024 Aug 12, 2024	BUY	$14.1 - $20.78 $23,518 - $34,661	1,668 Added 48.71%	5,092 $83,000
Q1 2024 May 10, 2024	BUY	$13.74 - $21.6 $12,833 - $20,174	934 Added 37.51%	3,424 $73,000
Q4 2023 Feb 09, 2024	BUY	$8.7 - $15.02 $21,593 - $37,279	2,482 Added 31025.0%	2,490 $36,000
Q3 2023 Nov 09, 2023	SELL	$8.96 - $10.75 $45,911 - $55,083	-5,124 Reduced 99.84%	8 $0
Q2 2023 Aug 10, 2023	SELL	$9.39 - $12.18 $255,708 - $331,685	-27,232 Reduced 84.14%	5,132 $56,000
Q1 2023 May 11, 2023	BUY	$9.4 - $12.82 $304,221 - $414,906	32,364 New	32,364 $331,000
Q2 2022 Aug 10, 2022	SELL	$5.35 - $10.11 $1,407 - $2,658	-263 Reduced 75.36%	86 $1,000
Q1 2022 May 12, 2022	SELL	$7.93 - $13.33 $16,890 - $28,392	-2,130 Reduced 85.92%	349 $3,000
Q4 2021 Feb 10, 2022	SELL	$11.96 - $19.35 $5,633 - $9,113	-471 Reduced 15.97%	2,479 $33,000
Q3 2021 Nov 10, 2021	BUY	$17.35 - $24.87 $51,182 - $73,366	2,950 New	2,950 $53,000

Others Institutions Holding CELC

# of Institutions

107

Shares Held

30.3M

Call Options Held

30.8K

Put Options Held

152K

View Full List

About Celcuity Inc.

Ticker CELC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,941,300
Market Cap $198M
Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...

More about CELC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account